IL-17 Blockade to Decrease irAEs (REPLAY)

The primary objective of this study is to determine the safety and feasibility of administering an IL-17A (human IgG1κ) monoclonal antibody, (Secukinumab, Cosentyx®) to participants with metastatic melanoma who have previously received immune checkpoint inhibitor (ICI) therapy, experienced an immune related adverse event (colitis, hepatitis, skin rash, psoriatic arthritis) to ICI, and are re-initiating ICI therapy.

Trial Details

NCT ID
NCT07237594
Phase
PHASE1
Sponsor
Duke University
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Secukinumab Injection
Locations (sample)
  • Durham, North Carolina, United States|35.99403,-78.89862

Key Eligibility Criteria

  • Histologically confirmed advanced metastatic melanoma
  • Participants of any gender who are at least 18 years of age on the day of signing informed consent
  • Participants must be planned or scheduled by their treating physician to receive PD-1 therapy or PD-1 plus anti LAG3 or PD-1 plus anti CTLA-4 thera…
  • Participant (or legally acceptable representative if applicable) provides written informed consent for the trial

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →